Find Belzutifan manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Pt2977, 1672668-24-4, Mk-6482, Welireg, Mk6482, Belzutifan [inn]
Molecular Formula
C17H12F3NO4S
Molecular Weight
383.3  g/mol
InChI Key
LOMMPXLFBTZENJ-ZACQAIPSSA-N
FDA UNII
7K28NB895L

Belzutifan
Belzutifan is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.
1 2D Structure

Belzutifan

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]oxy]-5-fluorobenzonitrile
2.1.2 InChI
InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1
2.1.3 InChI Key
LOMMPXLFBTZENJ-ZACQAIPSSA-N
2.1.4 Canonical SMILES
CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O
2.1.5 Isomeric SMILES
CS(=O)(=O)C1=C2[C@@H]([C@@H]([C@@H](C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O
2.2 Other Identifiers
2.2.1 UNII
7K28NB895L
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3-(((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yl)oxy)-5-fluorobenzonitrile

2. Mk-6482

3. Mk6482

4. Pt-2977

5. Pt2977

6. Welireg

2.3.2 Depositor-Supplied Synonyms

1. Pt2977

2. 1672668-24-4

3. Mk-6482

4. Welireg

5. Mk6482

6. Belzutifan [inn]

7. Belzutifan [usan]

8. Pt-2977

9. 3-(((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yl)oxy)-5-fluorobenzonitrile

10. 7k28nb895l

11. 3-[[(1s,2s,3r)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1h-inden-4-yl]oxy]-5-fluorobenzonitrile

12. 3-{[(1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yl]oxy}-5-fluorobenzonitrile

13. 3-((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-methylsulfonylindan-4-yl)oxy-5-fluoro-benzonitrile

14. Benzonitrile, 3-(((1s,2s,3r)-2,3-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1h-inden-4-yl)oxy)-5-fluoro-

15. Belzutifan [who-dd]

16. Unii-7k28nb895l

17. Belzutifan [orange Book]

18. Chembl4585668

19. Schembl16560918

20. Gtpl11251

21. Pt 2977 [who-dd]

22. Bdbm373040

23. Dtxsid201334517

24. Pt 2977

25. Ex-a4441

26. Us9896418, Compound 289

27. Xrc66824

28. Nsc825217

29. Who 11196

30. At14994

31. Belzutifan (pt2977, Mk-6482)

32. Compound 2 [pmid: 31282155]

33. Nsc-825217

34. Mk-6482; Pt2977

35. Ac-35183

36. Hy-125840

37. Cs-0101119

38. A935088

39. Q27456641

40. 3-(((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methanesulfonyl)-2,3-dihydro-1h-inden-4-yl)oxy)-5-fluorobenzonitrile

41. 3-((1s,2s,3r)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1h-inden-4-yloxy)-5-fluorobenzonitrile

42. 72q

2.4 Create Date
2016-02-23
3 Chemical and Physical Properties
Molecular Weight 383.3 g/mol
Molecular Formula C17H12F3NO4S
XLogP32
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Exact Mass383.04391352 g/mol
Monoisotopic Mass383.04391352 g/mol
Topological Polar Surface Area95.8 Ų
Heavy Atom Count26
Formal Charge0
Complexity675
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Belzutifan exerts its therapeutic effects by inhibiting a transcription factor necessary for the growth of solid tumors associated with VHL disease. It is taken once daily at approximately the same time each day, with or without food. Both severe anemia and hypoxia have been observed following therapy with belzutifan, and patients should be monitored closely before and during therapy to ensure patients can be managed as clinically indicated. There are no data regarding the use of erythropoiesis-stimulating agents for the treatment of belzutifan-induced anemia, and as such these therapies should be avoided. Belzutifan may cause embryo-fetal toxicity when administered to pregnant women. Female patients and male patients with female partners of reproductive potential should ensure that an effective form of contraception is used throughout therapy and for one week after the last dose - as belzutifan appears to decrease the efficacy of systemic hormonal contraceptives, patients should be advised to use an additional method of contraception (e.g. condoms) to eliminate the possibility of pregnancy during therapy.


5.2 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


5.3 ATC Code

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01X - Other antineoplastic agents

L01XX - Other antineoplastic agents

L01XX74 - Belzutifan


5.4 Absorption, Distribution and Excretion

Absorption

In patients with VHL disease-associated renal cell carcinoma, the mean Cmax and AUC0-24h at steady-state - which was achieved after approximately three days of therapy - were 1.3 g/mL and 16.7 ghr/mL, respectively. The median Tmax is one to two hours following oral administration. The administration of belzutifan with food has a negligible effect on drug disposition - when given alongside a high-calorie, high-fat meal, the Tmax was delayed by approximately 2 hours with no other clinically meaningful effects observed.


Volume of Distribution

The steady-state volume of distribution of belzutifan following oral administration is approximately 130 L.


Clearance

The mean clearance of belzutifan following oral administration is 7.3 L/h.


5.5 Metabolism/Metabolites

Belzutifan is primarily metabolized by UGT2B17 and CYP2C19, and to a lesser extent by CYP3A4.


5.6 Biological Half-Life

The mean elimination half-life of belzutifan is 14 hours.


5.7 Mechanism of Action

Hypoxia-inducible factor 2 (HIF-2) is a transcription factor which aids in oxygen sensing by regulating genes that promote adaptation to hypoxia. In healthy patients, when oxygen levels are normal, HIF-2 is broken down via ubiquitin-proteasomal degradation by von-Hippel Lindau (VHL) proteins. In the presence of hypoxia, HIF-2 translocates into cell nuclei and forms a transcriptional complex with hypoxia-inducible factor 1 (HIF-1) - this complex then induces the expression of downstream genes associated with cellular proliferation and angiogenesis. Patients with von-Hippel Lindau (VHL) disease lack functional VHL proteins, leading to an accumulation of HIF-2, and this accumulation is what drives the growth of VHL-associated tumors. Belzutifan is an inhibitor of HIF-2 that prevents its complexation with HIF-1 in conditions of hypoxia or impaired VHL protein function, thereby reducing the expression of HIF-2 target genes and slowing/stopping the growth of VHL-associated tumors.


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734028200,"product":"BELZUTIFAN","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"APOTEX INC ETOBICOKE","customerCountry":"CANADA","quantity":"1.20","actualQuantity":"1.2","unit":"KGS","unitRateFc":"120000","totalValueFC":"141916.1","currency":"USD","unitRateINR":10048723.333333334,"date":"13-Dec-2024","totalValueINR":"12058468","totalValueInUsd":"141916.1","indian_port":"Hyderabad Air","hs_no":"29309099","bill_no":"6428695","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1737138600,"product":"BELZUTIFAN","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"APOTEX INCETOBICOKE","customerCountry":"CANADA","quantity":"4.10","actualQuantity":"4.1","unit":"KGS","unitRateFc":"120000","totalValueFC":"486918.1","currency":"USD","unitRateINR":10240623,"date":"18-Jan-2025","totalValueINR":"41986554.3","totalValueInUsd":"486918.1","indian_port":"Hyderabad Air","hs_no":"29309099","bill_no":"7402374","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
13-Dec-2024
18-Jan-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Welireg (belzutifan) is first and only HIF-2α inhibitor, being investigated for the treatment of 12 years and older with advanced, unresectable pheochromocytoma and paraganglioma (PPGL).


Lead Product(s): Belzutifan

Therapeutic Area: Oncology Brand Name: Welireg

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 14, 2025

blank

01

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : Welireg (belzutifan) is first and only HIF-2α inhibitor, being investigated for the treatment of 12 years and older with advanced, unresectable pheochromocytoma and paraganglioma (PPGL).

Product Name : Welireg

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 14, 2025

blank

Details:

Welireg (belzutifan), an oral HIF-2α inhibitor, being evaluated for the treatment of adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.


Lead Product(s): Belzutifan

Therapeutic Area: Rare Diseases and Disorders Brand Name: Welireg

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 18, 2025

blank

02

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : Welireg (belzutifan), an oral HIF-2α inhibitor, being evaluated for the treatment of adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Product Name : Welireg

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 18, 2025

blank

Details:

Welireg (belzutifan), an oral HIF-2α inhibitor, being evaluated for the treatment of adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.


Lead Product(s): Belzutifan

Therapeutic Area: Oncology Brand Name: Welireg

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 27, 2025

blank

03

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : Welireg (belzutifan), an oral HIF-2α inhibitor, being evaluated for the treatment of adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Product Name : Welireg

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 27, 2025

blank

Details:

Welireg (belzutifan) is first and only HIF-2α inhibitor, being investigated for the treatment of 12 years and older with advanced, unresectable pheochromocytoma and paraganglioma (PPGL).


Lead Product(s): Belzutifan

Therapeutic Area: Oncology Brand Name: Welireg

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 27, 2025

blank

04

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : Welireg (belzutifan) is first and only HIF-2α inhibitor, being investigated for the treatment of 12 years and older with advanced, unresectable pheochromocytoma and paraganglioma (PPGL).

Product Name : Welireg

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 27, 2025

blank

Details:

Welireg (belzutifan) is first and only hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for the adult patients with advanced renal cell carcinoma (RCC).


Lead Product(s): Belzutifan

Therapeutic Area: Rare Diseases and Disorders Brand Name: Welireg

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 13, 2024

blank

05

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : Welireg (belzutifan) is first and only hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for the adult patients with advanced renal cell carcinoma (RCC).

Product Name : Welireg

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 13, 2024

blank

Details:

HC-7366, a selective activator of general control nonderepressible 2 kinases, is under investigation with Welireg for clear cell renal cell carcinoma treatment.


Lead Product(s): HC-7366,Belzutifan

Therapeutic Area: Oncology Brand Name: HC-7366

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 05, 2024

blank

06

HiberCell

U.S.A
arrow
Discovery Europe
Not Confirmed

HiberCell

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : HC-7366, a selective activator of general control nonderepressible 2 kinases, is under investigation with Welireg for clear cell renal cell carcinoma treatment.

Product Name : HC-7366

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 05, 2024

blank

Details:

Welireg (belzutifan) is first and only hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for the adult patients with advanced renal cell carcinoma (RCC).


Lead Product(s): Belzutifan

Therapeutic Area: Oncology Brand Name: Welireg

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 14, 2023

blank

07

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : Welireg (belzutifan) is first and only hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for the adult patients with advanced renal cell carcinoma (RCC).

Product Name : Welireg

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 14, 2023

blank

Details:

Welireg (belzutifan) 40 mg tablet act as the HIF-2α inhibitor, which is investigated for the treatment of adult patients with advanced renal cell carcinoma.


Lead Product(s): Belzutifan

Therapeutic Area: Oncology Brand Name: Welireg

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 19, 2023

blank

08

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : Welireg (belzutifan) 40 mg tablet act as the HIF-2α inhibitor, which is investigated for the treatment of adult patients with advanced renal cell carcinoma.

Product Name : Welireg

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 19, 2023

blank

Details:

WELIREG (belzutifan) 40 mg tablet act as the HIF-2α inhibitor, which is investigated for the treatment of adult patients with advanced renal cell carcinoma


Lead Product(s): Belzutifan

Therapeutic Area: Oncology Brand Name: Welireg

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 18, 2023

blank

09

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Merck & Co

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : WELIREG (belzutifan) 40 mg tablet act as the HIF-2α inhibitor, which is investigated for the treatment of adult patients with advanced renal cell carcinoma

Product Name : Welireg

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 18, 2023

blank

Details:

The collaboration aims to evaluate HiberCell's HC-7366, a selective activator of the general control nonderepressible 2 kinases in combination with Welireg (belzutifan), Merck’s oral HIF-2α inhibitor for the treatment of clear cell renal cell carcinoma.


Lead Product(s): HC-7366,Belzutifan

Therapeutic Area: Oncology Brand Name: HC-7366

Study Phase: PreclinicalProduct Type: Other Small Molecule

Sponsor: Merck & Co

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 12, 2023

blank

10

HiberCell

U.S.A
arrow
Discovery Europe
Not Confirmed

HiberCell

U.S.A
arrow
Discovery Europe
Not Confirmed

Details : The collaboration aims to evaluate HiberCell's HC-7366, a selective activator of the general control nonderepressible 2 kinases in combination with Welireg (belzutifan), Merck’s oral HIF-2α inhibitor for the treatment of clear cell renal cell carcinom...

Product Name : HC-7366

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

May 12, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1672668-24-4 / Belzutifan API manufacturers, exporters & distributors?

Belzutifan manufacturers, exporters & distributors 1

40

PharmaCompass offers a list of Belzutifan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Belzutifan manufacturer or Belzutifan supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Belzutifan manufacturer or Belzutifan supplier.

PharmaCompass also assists you with knowing the Belzutifan API Price utilized in the formulation of products. Belzutifan API Price is not always fixed or binding as the Belzutifan Price is obtained through a variety of data sources. The Belzutifan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Belzutifan

Synonyms

Pt2977, 1672668-24-4, Mk-6482, Welireg, Mk6482, Belzutifan [inn]

Cas Number

1672668-24-4

Unique Ingredient Identifier (UNII)

7K28NB895L

About Belzutifan

Belzutifan is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.

Belzutifan Manufacturers

A Belzutifan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Belzutifan, including repackagers and relabelers. The FDA regulates Belzutifan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Belzutifan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Belzutifan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Belzutifan Suppliers

A Belzutifan supplier is an individual or a company that provides Belzutifan active pharmaceutical ingredient (API) or Belzutifan finished formulations upon request. The Belzutifan suppliers may include Belzutifan API manufacturers, exporters, distributors and traders.

click here to find a list of Belzutifan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Belzutifan USDMF

A Belzutifan DMF (Drug Master File) is a document detailing the whole manufacturing process of Belzutifan active pharmaceutical ingredient (API) in detail. Different forms of Belzutifan DMFs exist exist since differing nations have different regulations, such as Belzutifan USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Belzutifan DMF submitted to regulatory agencies in the US is known as a USDMF. Belzutifan USDMF includes data on Belzutifan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Belzutifan USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Belzutifan suppliers with USDMF on PharmaCompass.

Belzutifan NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Belzutifan as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Belzutifan API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Belzutifan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Belzutifan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Belzutifan NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Belzutifan suppliers with NDC on PharmaCompass.

Belzutifan GMP

Belzutifan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Belzutifan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Belzutifan GMP manufacturer or Belzutifan GMP API supplier for your needs.

Belzutifan CoA

A Belzutifan CoA (Certificate of Analysis) is a formal document that attests to Belzutifan's compliance with Belzutifan specifications and serves as a tool for batch-level quality control.

Belzutifan CoA mostly includes findings from lab analyses of a specific batch. For each Belzutifan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Belzutifan may be tested according to a variety of international standards, such as European Pharmacopoeia (Belzutifan EP), Belzutifan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Belzutifan USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty